ALACHUA, Fla.--(BUSINESS WIRE)--Nanotherapeutics, Inc. announced today enrollment of the first patient into a Phase II cervical cancer trial for Triapine®, sponsored by the Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI). Triapine® is a ribonucleotidereductase inhibitor (RNRi) that is under evaluation in combination with cisplatin and radiation as a radiosensitizing chemotherapeutic agent for women with advanced stage cervical and vaginal cancers. NCI and Nanotherapeutics are collaborating on the development of Triapine® under a Clinical Trials Agreement.
Help employers find you! Check out all the jobs and post your resume.
